atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
The Food and Drug Administration approved a gene therapy for severe leukocyte adhesion deficiency type 1 (LAD-1), an ultra-rare disease that leaves children vulnerable to life-threatening infections.
Read more here.
OpenAI launched ChatGPT Health and Anthropic added medical toolsets for Claude, meaning users can sync their records and wearables, using their personal health data to get hyper-specific answers to their medical questions. At the same time, the FDA issued new guidance…
Attendees
Sponsors and Exhibitors
Contact us